A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (NCT05203510)

🧪 Interventions in This Study

• Parenteral Treprostinil (DRUG)
• Oral Treprostinil (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• Banner University Medical Center (University of Arizona) — Phoenix, Arizona
• HonorHealth John C. Lincoln Medical Center — Phoenix, Arizona
• University of California San Francisco - Fresno — Fresno, California
• Cedars-Sinai Medical Center — Los Angeles, California
• University of California Davis Medical Center — Sacramento, California
• University of California San Francisco Pulmonary, Critical Care, Allergy and Sleep Medicine — San Francisco, California
• Hartford Hospital — Hartford, Connecticut
• USF — Tampa, Florida
• Georgia Clinical Research — Austell, Georgia
• Northwestern Memorial Hospital — Chicago, Illinois
• Indiana University Health North Hospital — Indianapolis, Indiana
• Community Health Network — Indianapolis, Indiana
• Brigham and Women's Hospital — Boston, Massachusetts
• Henry Ford Health System — Detroit, Michigan
• University of Nebraska Medical Center — Omaha, Nebraska
• Morristown Medical Center — Morristown, New Jersey
• University of Rochester Medical Center — Rochester, New York
• University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Duke University Medical Center — Durham, North Carolina
• University of Cincinnati — Cincinnati, Ohio
• The Ohio State University Wexner Medical Center — Columbus, Ohio
• Integris Baptist Medical Center — Oklahoma City, Oklahoma
• Oklahoma Heart Institute — Tulsa, Oklahoma
• Temple Hospital — Philadelphia, Pennsylvania
• Medical University of South Carolina — Charleston, South Carolina

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pulmonary Arterial Hypertension

• A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
• Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
• An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Aurora, Colorado
• ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California

Explore by condition: All Pulmonary Arterial Hypertension clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.